Valuation dashboard for Erasca, Inc. (ERAS) with P/E N/A, P/B 12.35, EV/EBITDA -17.66 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At $14.35 (closing price, October 30, 2026), ERAS has negative trailing earnings (P/E not meaningful) and an ROE of -80.43%. Market capitalisation stands at $5.0B.
Balance sheet quality for ERAS: current ratio of 10.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 12.35 |
| EV / EBITDA | -17.66 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.10 |
| vs Current Price | -99.3% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ERAS | Erasca, Inc. | $5.0B | 12.35 | -80.4% | |
| RVMD | Revolution Medicines, Inc. | $41.0B | 15.48 | -96.4% | |
| IDYA | IDEAYA Biosciences, Inc. | $3.1B | 2.45 | -16.5% | |
| TNGX | Tango Therapeutics, Inc. | $3.8B | 3.32 | -25.7% | |
| VRTX | Vertex Pharmaceuticals Incorporated | $141.7B | 32.53 | 7.01 | 23.3% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| REGN | Regeneron Pharmaceuticals, Inc. | $95.5B | 20.50 | 2.82 | 15.1% |
| MRNA | Moderna, Inc. | $88.5B | 12.99 | -39.2% |
Price
| Price | $14.35 (closing price, October 30, 2026) |
| Market Cap | $5.0B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -80.43% |
| Return on Invested Capital | -37.52% |
| Return on Assets | -66.02% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: RVMD · IDYA · TNGX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L
Explore sector: Healthcare · Biotechnology
More sections of ERAS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks